In this panel, Respiradigm will share what the team is building and why a robust regulatory and clinical trials strategy is non‑negotiable if you want to move fast without costly missteps.

We’ll start with the end in mind, visioning the product, defining a clear Target Product Profile (TPP), and then working backwards to map the clinical evidence package required for approval in priority markets.

Guest speaker Hugo LeMessurier will bring a clear, practical perspective with his catch cry: Australians often rush into a tiny human trial (with too few study subjects), which is an expensive detour. The smarter approach is to first confirm exactly what evidence regulators and payers will require, identify the gaps early, and design trials that directly de-risk approval and reimbursement.

The panel will also tackle the pragmatic questions founders and teams face:

• Where are the evidence gaps today?
• What preclinical/CMC/clinical pieces must be “decision-grade” before moving?
• Who is best placed to fund which parts—grants, strategic partners, VCs, or non-dilutive programs?

Expect a candid discussion focused on clarity, sequencing, and capital efficiency, so the next steps are the right steps.

ABOUT OUR SPEAKERS:

Hugo LeMessurier – LeMessurier Solutions

Hugo is an experienced entrepreneurial business leader with a proven track record of implementing complex business solutions in multinational and SME businesses within an international environment.

For over a decade Hugo has held directorships and senior management positions in start-up, listed and multinational organisations in the USA, EU and Australia. He has founded, sold and listed companies in healthcare, food, service and consulting industries. Hugo led an Australian biotechnology company through technology acquisition, regulatory approval, commercial launch and public listing and has experience in preparing and guiding companies through listing on the Australian and Newcastle Stock Exchanges.

Hugo is currently a director or mentor of a number of businesses commercialising innovative technologies and is an active founder and investor in early-stage technology companies.

Dr Anya Jones – Co-Founder & CEO, Respiradigm

Anya is an accomplished scientific and entrepreneurial leader with a strong track record in advancing immunology, genomics and health technology innovation within academic and commercial environments. For over a decade, Anya has held research leadership roles across multidisciplinary teams in Australia, and as Co-Founder and CEO of Respiradigm she is driving the development of new approaches to asthma prevention. She has led major genomics and immunology programs, including studies on allergen immunotherapy, bacterial lysate-based immune training and large-scale birth cohort investigations.

Anya is also an active advocate for STEM education and science communication, delivering talks, workshops and hands-on programs that make complex research accessible and inspire emerging scientists. She is an alumna of the global Homeward Bound leadership program, contributing to initiatives strengthening women’s leadership in STEM.

Anya currently leads Respiradigm through its next stage of scientific and commercial progression and continues to support programs advancing scientific innovation and empowering future STEM leaders.

MEET THE MODERATOR:

Ian Brown – Co-Founder and Executive Chairman, Respiradigm

Ian is an experienced entrepreneurial leader and venture builder with a strong record of creating value-driven companies and guiding breakthrough innovation toward global impact.

For over a decade, Ian has worked across international markets, holding leadership, advisory and board roles in deep tech, healthtech and venture creation. As Co-Founder and Executive Chairman of Respiradigm, he leads international partnerships, capital strategy and ecosystem development, uniting research organisations, clinicians and investors around a shared mission to transform the prevention and management of asthma.

+PLUS! Founders and early-stage teams can access limited 1-1 consultation sessions with Hugo – your opportunity for personalised advice from a leader who has founded, scaled, listed and exited companies across multiple sectors. Spots are available on Tuesday 3 Feb and Thursday 5 Feb and are extremely limited, so early registration is essential.

The seminar event and office hours sessions are delivered by Respiradigm under the Entrepreneur in Residence Scheme from the Department of Energy and Economic Diversification, supported by the WA Life Sciences Innovation Hub.